Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346135 · ClinicalTrials.gov registry record · Phase 2
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
A Phase 2 study of Plasma Cell Myeloma and Secondary Amyloidosis, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 2
- Study locations
NCT03346135: Active Phase 2 study of Plasma Cell Myeloma and Secondary Amyloidosis, sponsored by City of Hope Medical Center.
NCT03346135 is a Phase 2 study of Plasma Cell Myeloma and Secondary Amyloidosis that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 31 participants, below the 207-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03346135, a Phase 2 study of Plasma Cell Myeloma and Secondary Amyloidosis, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
Primary Outcome
Will be estimated using the product-limit method of Kaplan-Meier.
Conditions Studied
Interventions
- DRUG Melphalan
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Daratumumab
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
Study Locations (2)
California
- City of Hope Medical Center - Duarte
Tennessee
- Sarah Cannon Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-07-17 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 2 |
What the registry record for NCT03346135 still lists
NCT03346135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 207-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Melphalan is the first listed.
NCT03346135 reports a single indexed study location in California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03346135 about?
NCT03346135 is a clinical study titled "Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma". This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
What is the current status of trial NCT03346135?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2019-07-17. Estimated completion is 2026-07-01.
What conditions does trial NCT03346135 study?
This clinical trial studies the following conditions: Plasma Cell Myeloma, Secondary Amyloidosis.
What interventions are being tested in trial NCT03346135?
The interventions under investigation include: Melphalan (DRUG), Laboratory Biomarker Analysis (OTHER), Daratumumab (BIOLOGICAL), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT03346135?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03346135 being conducted?
This trial has 2 study locations across California, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03346135's enrollment target sits among peer trials
31 24th of 32 higher than 9 of 32 other Plasma Cell Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plasma Cell Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
RECRUITING · Phase 2
-
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Lenalidomide Maintenance in Plasma Cell Myeloma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI